DCVC Bio

A look at what @DCVC /@DCVCBio founders delivered /this week/: 💪 🚚 🤖 Fleet-scale humanoid deployment: @agilityrobotics expanded its commercial footprint with GXO Logistics, soon moving into facilities across North Carolina and Tennessee after crossing an unprecedented 100,000-tote operational milestone. ⚛️ Microreactor regulatory progress: @RadiantNuclear cleared a major hurdle as the US Dep't of @ENERGY approved the documented safety analysis for its Kaleidos test unit at @INL, moving it one step closer to criticality. 🧬 Predictive computational biology: Latus Bio published the first predictive computational model of Huntington’s disease built on human data in Nature Communications, along with preclinical data supporting its gene therapy candidate LTS-201 as a potentially disease-modifying treatment. This is BIG. 🔬 Rapid stem cell reprogramming: @SyntaxBio drew major biotech coverage for using its CRISPR-based Cellgorithm platform to differentiate human stem cells into pancreatic beta cells in just four days, an early step toward faster development of cell therapies for Type 1 diabetes. 🎯 Clinical precision oncology: @FrontierMeds posted a standout 56% confirmed response rate in its Phase 1 lung cancer trial (FMC-376) presented at the ESMO - European Society for Medical Oncology Congress. 💡 Quantum photonics breakthrough: @NVisionQuantum published research introducing the first organic molecule capable of directly linking quantum processors with light, unlocking a scalable path for optical quantum networking. 🧠 Frontier AI compute architecture: Unconventional AI (@unconvAI) AI CEO @NaveenGRao joined @20vcFund to talk about why inference could be a $10 trillion market and why robotics could be 100x bigger than coding agents. Onward!